Prolepsia forecastYes / no
Will NIH's budget for fiscal 2028 be lower than its budget for fiscal 2026?
As of 18 November 2026, Prolepsia puts the chance of yes at 13%.
13%chance of yes
How Prolepsia reasons
The report Prolepsia wrote with this forecast.
How forecasts are made · Track record
TL;DR
Probability of Yes: 13.2%; Probability of No: 86.8%. As of November 18, 2026, the likeliest outcome is that NIH’s final FY2028 program-level funding stays at or above its FY2026 level in nominal dollars, excluding ARPA-H. The main risk is a spending freeze that leaves expiring funding unreplaced, not Congress adopting the White House’s proposed cuts wholesale.
Key evidence
The NIH appropriations history and Congressional Research Service put the FY2026 benchmark at $47.4931 billion excluding ARPA-H. In the CRS historical series, only four of 29 overlapping two-year comparisons ended in a nominal decline. Congress also enacted that FY2026 total after the administration requested $27.915 billion, a concrete sign that the presidential request is a poor guide to what Congress will enact.
On comparable accounting, the House proposal sits about $75 million below the benchmark and the Senate draft about $120 million above it, after adding each chamber’s proposed Superfund research funding and the mandatory diabetes funding already enacted for FY2027. Neither is law. Senator Patty Murray’s November 16 push for a stopgap into January modestly strengthens the prospect that the incoming Congress negotiates a FY2027 settlement with some room above the baseline.
Uncertainties
The current stopgap holds FY2027 funding at FY2026 rates only through December 11, 2026. The final FY2027 total, the amount and duration of any diabetes funding renewal, and the terms of a FY2028 spending deal remain open. A full-year stopgap that freezes most accounts without replacing expiring funds could still produce a small nominal cut. Conversely, flat nominal funding resolves NO even if NIH loses purchasing power.
Read the full report
TL;DR
Probability of Yes: 13.2%; Probability of No: 86.8%. The forecast favors NIH’s final FY2028 funding matching or exceeding its FY2026 level because Congress has resisted deep cuts. The main route to YES is a freeze that leaves expiring funding unreplaced.
Context
As of November 18, 2026, NIH is operating under a continuing resolution that maintains FY2026 funding rates through December 11, 2026. The House and Senate have put forward FY2027 proposals, but there is no full-year settlement. The eventual FY2027 amount matters because it sets the starting point for FY2028 negotiations, not because it determines the answer.
The benchmark is $47.4931 billion in FY2026 enacted program-level funding, excluding ARPA-H, as shown by the NIH appropriations history and the May 18 CRS report. The question compares final funding on the same accounting basis in both years, including applicable transfers, supplementals and rescissions. It does not compare presidential requests, grant payments or inflation-adjusted purchasing power. A tie resolves NO.
Evidence
Nominal declines over two years have been uncommon. Of the 29 overlapping two-year comparisons in the FY1996–FY2026 CRS series, four ended below their starting level. They ended in FY2012, FY2013, FY2014 and FY2025. The same series shows six declines in 30 one-year comparisons. These are useful reference points, not independent trials. The long series includes the NIH budget-doubling era, and it generally excludes emergency supplementals, which the resolution criteria include when attributable to the relevant year.
FY2025 is the closest precedent for the main downside. NIH lost about $276 million even though most accounts were held flat under a full-year stopgap. The Innovation Account alone fell by $280 million. The precedent shows why the wording of a continuing resolution matters more than its label: Congress can hold the main accounts steady and still enact less funding in total. Past fiscal pressure has not always produced cuts, either. Under the caps set by the 2019 debt-limit deal, NIH funding rose 6% in FY2020 and 3% in FY2021 (CRS funding history).
Current appropriations behavior points the same way as the longer historical record. The administration requested $27.915 billion for FY2026, and Congress enacted $47.4931 billion instead (CRS). The administration again proposed reductions for FY2027, but neither chamber’s draft adopts cuts on that scale. One telling detail is the Public Health Service evaluation transfer. Both congressional drafts keep it at about $1.427 billion, while the administration requested $260 million. That is a specific source of NIH funding that both drafts preserve, not just a promise to protect the topline (House committee report; HHS budget request).
The FY2027 proposals are close to the benchmark once the same items are counted. The House proposal provides $47.316 billion in Labor–HHS funding and evaluation transfers after excluding ARPA-H. The Senate draft provides $47.490 billion on the same basis. Add each chamber’s proposed Superfund research amount and the $50.411 million in type 1 diabetes funding already enacted for the first part of FY2027, and the illustrative totals are about $47.418 billion for the House and $47.613 billion for the Senate. That is roughly $75 million below the benchmark and $120 million above it, respectively. These are comparisons of proposals plus existing law, not two enacted totals. With $200 million in full-year diabetes funding instead, both illustrative totals would clear the benchmark (House committee report; Interior funding proposal).
The politics favor protection without guaranteeing it. Democrats won both chambers and will write the FY2028 bills while President Trump retains a veto. Senator Patty Murray’s November 16 rejection of the Republican spending topline and push for a stopgap into January slightly strengthens the case for a FY2027 settlement with some room above the FY2026 level. It gives the incoming Congress a better chance to write the deal. It does not establish that a deal will happen or what NIH would get in it.
What's non-obvious
The headline figures can make NIH look safer than it is. The Senate draft’s $48.990 billion figure includes $1.500 billion for ARPA-H, which does not count here. The comparable Labor–HHS amount is $47.490 billion before adding other sources. The opposite mistake is to take a lower FY2026 comparison figure from the administration’s budget request at face value. That figure removes funding for a proposed transfer of environmental health programs and nets an inspector-general transfer. It does not show that Congress enacted a lower FY2026 total.
A freeze can be a cut even if no one votes to reduce the ordinary base. FY2026 included $226 million from the expiring Cures Act Innovation Account and $200 million in mandatory type 1 diabetes funding (CRS). If all other FY2026 funding stayed flat and neither source were replaced, the total would be $426 million lower. The congressional drafts do replace the expiring Cures dollars at the agency level, so that example is not a prediction of the negotiated budget. It shows why a thin FY2027 margin and the exact terms of a FY2028 freeze matter more than the size of the White House’s proposed cut.
Uncertainties
The next useful number is the final FY2027 program-level total on the same basis as FY2026. A settlement well above the benchmark gives NIH room to absorb a small cut in FY2028 without resolving YES. A settlement near or below the benchmark makes a carry-forward more consequential. The amount of any diabetes renewal specifically attributable to FY2028 matters more than a renewal headline, and no such amount is established as of the forecast date.
A broader nondefense spending agreement or debt-limit bargain could put pressure on NIH even if there is little support for singling it out. The timing makes that a risk, not an enacted constraint. The evidence that would settle it is the final legal funding for FY2028, including any full-year continuing resolution, supplementals or rescissions. If Congress reorganizes NIH in the meantime, the comparison will also need an authoritative accounting that keeps the two years comparable.
Forecast history
| Date | Forecast |
|---|---|
| 13% chance of yes |
Sources Prolepsia read
- continuing resolutionwww.govinfo.gov
- # NATIONAL INSTITUTES OF HEALTHofficeofbudget.od.nih.gov
- National Institutes of Health (NIH) Funding: FY1996-FY2026 - EveryCRSReport.comwww.everycrsreport.com
- FY 2027 Budget in Briefwww.hhs.gov
- Democrats win the US House and Senate as voters deliver a strong rebuke to Trump and Republicansapnews.com
- Murray on Senate Republicans Releasing More FY27 Appropriations Bills | Sen. Patty Murray (D-WA) | Forthwww.forth.news
- NOT-OD-26-059: Notice of Fiscal Policies in Effect for FY 2026grants.nih.gov
- Committee Approves FY27 Labor, Health and Human Services, and Education Appropriations Act | House Committee on Appropriations - Republicansappropriations.house.gov
The question
This question asks whether the National Institutes of Health (NIH) will receive a lower total federal budget in fiscal year 2028 (FY2028, October 1, 2027, through September 30, 2028) than it received in fiscal year 2026 (FY2026, October 1, 2025, through September 30, 2026). The comparison uses nominal U.S. dollars, without adjusting for inflation, and is based on total enacted NIH program-level funding rather than the President's proposed budget, actual expenditures, or grant obligations. For FY2026, Congress enacted approximately $47.493 billion in NIH program-level funding through appropriations legislation signed into law in early 2026. This represented an increase of approximately 1% over FY2025. The FY2026 figure includes funding from NIH appropriations, transfers from the Public Health Service evaluation set-aside, and other applicable funding sources, but excludes the Advanced Research Projects Agency for Health (ARPA-H), which is accounted for separately. The Trump administration had initially proposed substantially deeper cuts to NIH funding for FY2026, but Congress rejected those reductions. The administration subsequently proposed reductions for FY2027, although congressional appropriations decisions remained unsettled as of November 18, 2026. NIH was operating under a continuing resolution for FY2027 that maintained funding at FY2026 levels through December 11, 2026. The question concerns whether the final enacted funding available to NIH for FY2028 will fall below the FY2026 baseline of approximately $47.493 billion, regardless of the funding level enacted for FY2027. Background sources include the NIH Office of Budget (https://officeofbudget.od.nih.gov/), the NIH FY2026 fiscal policy notice (https://www.grants.nih.gov/grants/guide/notice-files/NOT-OD-26-059.html), and the Congressional Research Service report 'National Institutes of Health (NIH) Funding: FY1996-FY2026' (https://www.everycrsreport.com/reports/R43341.html).
How it resolves
The question resolves YES if NIH's final enacted total program-level funding for FY2028 is strictly less than its final enacted total program-level funding for FY2026, measured in nominal U.S. dollars using a consistent accounting methodology. It resolves NO if FY2028 funding is equal to or greater than FY2026 funding. The primary resolution source will be the NIH Office of Budget's official budget and appropriations publications, including its historical appropriations tables and congressional justification documents. If those documents do not provide comparable final figures, the Congressional Research Service's NIH funding reports will serve as the preferred secondary source, followed by official appropriations legislation and accompanying congressional explanatory statements. The comparison will include regular and supplemental appropriations attributable to the respective fiscal years, applicable transfers, and other components included in NIH's officially reported total program-level funding. ARPA-H funding will be excluded from both years, even if its administrative relationship with NIH changes. Any reorganizations, transfers of institutes or programs, or accounting changes between FY2026 and FY2028 should be handled using comparable funding totals wherever an authoritative reconciliation is available. The comparison will use final enacted funding levels, incorporating supplemental appropriations, rescissions, and other legislative adjustments attributable to each fiscal year, rather than initial appropriations alone. If FY2028 begins under a continuing resolution, the question will remain unresolved until full-year funding is established or until final fiscal-year funding can otherwise be determined. If Congress never enacts a full-year FY2028 appropriation, the final legally authorized funding for FY2028, including funding provided through continuing resolutions, will be used. Resolution should ordinarily occur after September 30, 2028, once final funding information is available. If an official FY2028 funding amount cannot be established, or if organizational changes make a meaningful comparison impossible and no authoritative reconciliation exists, the question will be annulled rather than assigned an arbitrary outcome.
Fine print
The comparison is between nominal federal funding amounts, not inflation-adjusted purchasing power. A nominal increase that fails to keep pace with inflation will therefore resolve NO. The question measures budgetary resources allocated to NIH, not the amount actually spent, obligated, or distributed to researchers. Funding proposed by the President or congressional committees does not count unless enacted into law. Supplemental appropriations and rescissions count only when attributable to the fiscal year being measured, and prior-year unobligated balances carried forward do not count as new funding. The FY2026 reference amount is approximately $47.493 billion, but the precise figure established by the designated authoritative sources will govern resolution. The same program-level accounting conventions must be used for both fiscal years. If NIH is substantially reorganized, the comparison should follow the budgetary entity and activities officially classified as NIH, subject to any authoritative adjustments necessary to preserve comparability. A reduction of even one dollar relative to the FY2026 reference amount qualifies as YES.
More public forecasts
Will the US federal budget deficit for fiscal year 2027 exceed $2 trillion, as reported by the US Treasury?
66%chance of yes
Prolepsia forecast
Will China's official defence budget for 2027 grow by more than 7%?
57%chance of yes
Prolepsia forecast
Will EU leaders agree the 2028 to 2034 long-term EU budget before 31 December 2027?
90%chance of yes
Prolepsia forecast
Will China raise its official budget deficit target above 4% of GDP at the March 2027 National People's Congress?
36%chance of yes
Prolepsia forecast
Will the US average effective tariff rate be above 15% on 31 December 2027, as measured by the Yale Budget Lab?
16%chance of yes
Prolepsia forecast
Will Congress give the Golden Dome missile defense program more than USD 20 billion in fiscal year 2028 funding?
12%chance of yes
Prolepsia forecast